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Abstract
Considerable research is aimed at determining the
mechanisms by which hormone-refractory prostate
cancer develops. In an effort to assist in the under-
standing of recurrent prostate cancer and the cellular
processes that mediate this disease, a mathematical
model is presented that describes both the pretreat-
ment growth and the posttherapy relapse of human
prostate cancer xenografts. Our goal is to evaluate the
interplay between the multiple mechanisms that have
been postulated as causes of androgen-independent
relapse. Simulations of the model show that molecular
events that render the androgen receptor irrelevant to
disease progression, such as upregulation of BCL2,
can result in relapse after androgen deprivation
therapy. However, decreased apoptosis of androgen-
independent cells alone overestimates the effects of
hormone therapy when compared to experimental
data. When decreased apoptosis is combined with
continual androgen receptor activation, the post-
therapy growth dynamics are in excellent correlation
with experimental observations of the growth of
LuCaP xenografts. Furthermore, the mathematical
model predicts that upregulation of the androgen
receptor, together with its increased activation, is
alone sufficient to result in the androgen-independent
growth of LNCaP xenografts. Recent experimental
studies that suggest that the posttherapy increase in
and continual activation of the androgen receptor are
common and crucial features of recurrent prostate
cancer provide validation of the model predictions.
This approach provides a framework for using math-
ematical techniques to study novel therapeutic strat-
egies aimed at controlling this disease.
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Introduction
For American men over the age of 40, prostate cancer is
now the most commonly diagnosed cancer and the second
leading cause of cancer-related deaths [1]. Prognosis is
generally favorable for most early-detected cases of local-
ized prostate cancer. However, in some patients, the disease is
very aggressive and even the initial diagnosis shows signs of
invasion and metastasis [2]. For this advanced stage of dis-
ease, the cornerstone of treatment is androgen deprivation
therapy (ADT), a type of hormone therapy in which the body is
deprived of androgens through surgical or chemical castration
[3–6]. ADT ceases androgen production from its primary
source, the testes; however, this does not ensure its elimination
from the plasma and body tissues. A small amount is produced
by a secondary source, the adrenal glands, and this fount may
not be affected by surgical or chemical castration [4]. Although
most patients have a positive initial response to ADT, this is
usually temporary. Unfortunately, the prognosis is still unfavor-
able due to the acquisition of an androgen-independent (AI)
phenotype that is resistant to secondary endocrine therapy and
to chemotherapy [6,7]. At the present time, there is no effective
therapeutic option for or clear understanding of the causes of
hormone-refractory prostate cancer.
The postulated mechanisms to explain AI relapse include
amplification or mutation of the androgen receptor gene (AR),
ligand-independent activation of the androgen receptor and
alternate signaling pathways, which bypass the growth-pro-
moting functions of the androgen receptor [4,8,9]. Many alter-
ations in the AR have been detected in prostate cancers and a
subset of these effect the ligand specificity of the receptor,
permitting its activation by nonandrogens or even antiandro-
gens [10]. This gain of function of the androgen receptor can
result in hormone-resistant prostate cancer through the acqui-
sition of AI mechanisms for activation of the androgen receptor
[11]. Most patients do not have AR mutations or amplifications,
yet they retain active androgen receptor signaling after therapy.
Ligand-independent routes to receptor activation could poten-
tially result from increased protein kinase signaling, mediated
by oncogenes [12]. Another possible cause of hormone re-
sistance is that the growth-regulatory effects of the andro-
gen receptor can be overridden by alternative, androgen
Abbreviations: AD, androgen-dependent; ADT, androgen deprivation therapy; AI, androgen-
independent; AR, androgen receptor; NSE, neuron-specific enolase
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receptor– independent signaling pathways such as the over-
expression of the antiapoptotic protein BCL2 [12,13].
In an effort to understand the biologic characteristics of
hormone-refractory prostate cancer, several experimental
model systems have been derived. Currently, however, only
a few models exist that exhibit the features of human
prostate cancer growth [6]. In 1996, Ellis et al. [14] charac-
terized a novel, androgen-sensitive, human prostate cancer
xenograft, LuCaP 23. The LuCaP 23 xenografts were devel-
oped from human prostatic cancer metastases harvested at
autopsy and propagated in athymic mice. These cells se-
crete large amounts of prostate-specific antigen (PSA) and
exhibit many of the characteristics of clinical prostatic carci-
noma, including the resumption of growth after ADT. Sub-
sequent studies found that LuCaP 23.1 is composed of at
least two tumor cell populations representing two different
phenotypes: one is neuron-specific enolase (NSE) positive
and the other is NSE negative [13]. Furthermore, the NSE-
positive tumors, which were recovered after AI relapse in
castrated hosts, also expressed BCL2, a gene product
known to inhibit apoptosis. More recently, Chen et al. [12]
found that hormone-refractory LuCaP tumors had more
androgen receptor protein than their parental hormone-sen-
sitive counterparts. This suggests that multiple mechanism
for the acquisition of AI prostate cancer may be at work.
In this paper we present the first experimentally driven
mathematical model designed to investigate interplay be-
tween the possible mechanisms of AI relapse. Comparing
the model to the experimental data of LuCaP 23 xeno-
grafts shows that increased BCL2 expression, which
inhibits apoptosis in AI cells, can result in AI relapse but
in a way that is incompatible with the experimental data.
However, combining decreased apoptosis with continued
proliferation of a subset of androgen-dependent (AD) cells
results in tumor relapse, which is consistent with experi-
mental observations. These results suggest that the con-
tinual posttherapy activation of the androgen receptor is a
crucial component of recurrent prostate cancer associated
with the LuCaP xenografts. Furthermore, blocking the
upregulation of the androgen receptor and thereby reduc-
ing the proliferation of AD cells could lead to significantly
longer remissions.
We also compare the mathematical model to experimen-
tal data presented in Ref. [12] for the growth of LNCaP
tumors in castrated mice. In this case, the model agrees
with the experimental evidence that increased androgen
receptor activation alone is sufficient to result in hormone-
refractory tumor growth.
Methods
The goal of this study is to test the leading hypotheses for AI
relapse through the development and simulation of a math-
ematical model that describes prostate tumor growth before
and after hormone therapy. The tumor is viewed as a densely
packed, radially symmetric sphere of radius R(t). Cell move-
ment is produced by the local volume changes that accom-
pany cell proliferation and death. The spheroid expands or
shrinks at a rate that depends on the balance between cell
growth and division and cell death within the tumor volume,
the former and latter being meditated by the presence of
androgen, a(r, t).
Tumor Growth Model
Prostatic cancer cells, like the normal prostatic cells from
which they arise, are sensitive to androgen stimulation of
their growth. The presence of androgen stimulates the daily
proliferation of these AD cells while inhibiting their daily
percentage of apoptotic death [7,15]. Therefore, before
treatment continuous net growth occurs. In contrast, after
ADT, the proliferation rate of AD cells is significantly reduced
and the rate of cellular suicide is increased [7,15,16]. This
results in a decline in the number of AD cells within the tumor
and an initial positive response. However, in many prostate
micrometastases there is also a heterogeneous presence of
AI cancer cells whose proliferation rate exceeds their apo-
ptotic death rate even after total androgen blockage is
performed [7]. In the LuCaP 23 experiments, AI cells were
undetectable before therapy [14]. After ADT, AI cells, which
are characterized as being NSE-positive and containing
large quantities of BCL2, were harvested [13].
Based on these findings, we first consider a polyclonal
tumor consisting of a heterogeneous mix of two cells types
(AD and AI, with AI cells being below detectable levels
initially) as the mechanism by which AI relapse can occur.
The governing equations for the tumor cell populations are
derived by applying the principle of conservation of mass to
each phenotype. For solid tumor growth, it is widely assumed
that cell movement has two components: 1) net collective
motion due to the velocity generated by cell growth and
death [17–20] and 2) random motility [18–22]. Based on
these assumptions, statements of balance may be written as
follows for AD cells, p, and AI cells, q.
In Equations (1) and (2) Dp and Dq are the assumed
constant random motility coefficients of the two types of
tumor cells and ap(a), aq(a), dp(a), and dq(a) are their respec-
tive proliferation and programmed death rates. These cell
proliferation and apoptotic rates are crucially dependent on
Bp
—
Bt + j  (up) = DpDp + ap(a)p  dp(a)p, (1)
Time rate Collective Random Androgen- Androgen-
of change + cellular = cellular + mediated  mediated
of AD cells motion motion proliferation apoptosis
Bq
—
Bt + j  (uq) = DqDq + aq(a)q  dq(a)q, (2)
Time rate Collective Random Androgen- Androgen-
of change + cellular = cellular + mediated  mediated
of AI cells motion motion proliferation apoptosis
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the local androgen concentration, a(r, t), and their specific
characteristics will be discussed in detail in the hormonal
effects subsection to follow.
To assess the tumor’s response to ADT it will be important
to follow the evolution of the tumor volume (= 4/3pR3, for
radial symmetry) or, equivalently, the tumor radius R(t). We
do this by noting that under radial symmetry, the tumor radius
expands at a rate that is equal to the radial component of the
velocity there, i.e.,
An equation for the tumor velocity is obtained by adding
Equations (1) and (2) with the additional constraint that there
are no voids within the tumor so that p + q = 1. Implied by this
model formulation is that we begin with a tumor of given initial
cell density, p0, q0; radius, R0; and androgen concentration,
a0. By symmetry, at the center of the tumor (r = 0) there is no
flux of androgen and the local velocity is zero. Finally, for the
tumor cell populations, we impose no flux of p and q at the
tumor center and on its outer boundary.
Androgen Levels
The androgen levels within the tumor are assumed
constant until the time of treatment. ADT results in the
partial blockage of androgen production and the tumor
levels will rapidly decrease to a new, significantly lower,
steady state.
Hormonal Effects
The exponential decline of androgen after ADT causes an
increase in the apoptotic death rate of AD cells and a
decrease in their proliferation [7,16]. A further consequence
of therapy is a decrease in the apoptotic rate of AI cells with
no significant difference in their proliferation rate when com-
pared to untreated tumor cells [7]. The effect of androgen on
proliferative and apoptotic activity is thus modeled by giving
the growth and death rates ap(a), aq(a), dp(a), and dq(a) these
experimentally determined characteristics. Figure 1 illus-
trates how cell kinetics varies with androgen availability.
The function ap(a) is chosen so that when androgen is in
excess, AD cells proliferate at constant rate, a1. After ADT,
the androgen levels drop quickly and cells proliferate at a
fraction of their pretreatment value, a1h1, where h1 repre-
sents the growth rate in the absence of androgen relative to
its value when androgen is abundant. In keeping with exper-
imental observations [7], the function aq(a) is chosen so that
androgen concentration has no effect on the proliferation
rate of the AI cells; in other words aq(a) = a2 u constant.
The functions dq(a) and dq(a) also suggest that when the
androgen supply is plentiful, the cells die at rates d1 and d2,
respectively. When androgen levels fall, the death rate of the
AD cells increases to the higher rate d1x1. However, in low-
androgen environments, increased BCL2 renders the AI
cells less susceptible to apoptosis and their death rate
decreases to d2x2. The parameters x1 and x2 represent
the respective death rates in the absence of androgen
relative to their values when androgen is abundant. Based
on experimental evidence [7,13], we assume that xq < 1 and
xp > 1. Because AD cells are dominant when androgen is
Figure 1. The effect of androgen concentration on the proliferation and apoptotic rates of AD cells (A) and AI cells (B). The circles indicate posttherapy androgen
concentrations and the respective proliferation and death rates.
dR
dt
¼ uðRðtÞ; tÞ; ð3Þ
Time rate of change ¼ Tumor velocity at
of the tumor radius the tumor boundary
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abundant [7,14], we will assume a1c a2, d1 < d2, and a2 < d2.
This last inequality assures that AI cells are below detectable
levels before therapy is initiated (see Figure 1).
Where possible, we make use of published data for the
treatment of athymic mice that have been implanted with
human prostate cancer xenograft LuCaP 23.1. For those
parameters for which no experimental data are available,
the goal is to quantify their influence on the model
behavior. Table 1 lists each parameter, its baseline value,
and source.
Results
Numerical Simulations
Numerical simulations of Equations (1)– (3) are per-
formed to investigate the tumor’s response to ADT for
various parameter values. The fit of the mathematical model
to the experimental data [14] for intact male mice bearing
LuCaP 23.1 xenografts is shown in Figure 2. The prolifera-
tion rate, a1 = 0.4621 per day, is based on the cells dividing
once every 36 hours; therefore, the best fit of the model
to this data allows for the estimation of the apoptotic rate,
d1 = 0.3812 per day. Together, these parameters result in a
tumor-doubling time of 8.6 days.
The range of behaviors the model can exhibit once ADT
has been initiated is depicted in Figure 3A. All parameters
are taken from Table 1 with x1 = 1.35 and x2 varying
between 0.25 and 1.0. In these simulations, polyclonality
and decreased apoptosis of AI cells are the only operative
mechanisms for tumor relapse. In other words, the increased
activation of the androgen receptor (through amplification
other pathways) is not considered here as evidenced by the
negative net growth rate of the AD cells. The model predicts
that for certain parameter values, ADT can result in control
of the tumor or in AI relapse. Notice that when x2, which
represents the amount by which the apoptotic rate is reduced
in the absence of androgen, is equal to unity (corresponding
to no decreased apoptosis of AI cells) the tumor regresses.
As x2 increases, corresponding to an increase in BCL2
expression and decreased apoptosis, the model predicts
that the tumor response to therapy ranges from prolonged
remission (x2 = 0.75) to rapid relapse (x2 = 0.25). Further-
more, the androgen-sensitive period is always characterized
by a marked decrease in tumor volume and both the rate of
posttherapy tumor growth and the time of relapse increase
and x2 decreases.
Figure 3B highlights the phases of tumor growth before
and after ADT withx2 = 0.5. From this simulation, it is evident
that the model captures the exponential pretreatment tumor
growth, the transient androgen-sensitive period immediately
after treatment, and the return to exponential growth in the
absence of androgen.
Further information regarding tumor growth and the
mechanism for relapse can be gleaned from Figure 4 where
the temporal variations in the proliferative activity and apo-
ptotic activity are plotted. These quantities are defined as the
total cellular proliferation (or death) within the tumor:
Proliferative activity ¼ apðaÞp þ aqðaÞq
Apoptotic activity ¼ dpðaÞp þ dqðaÞq
From Figure 4, it is clear that there are specific times for
which proliferative activity exceeds apoptotic activity, result-
ing in net growth. During the androgen-sensitive period, the
apoptotic activity surpasses the proliferative activity resulting
in tumor regression. The model also predicts that AI relapse
is associated with a decrease in apoptotic activity without an
increase in proliferation. This result is in agreement with
experimental observations, which found that whereas the
BUdR index remained at 50% of the pretherapy value for
Table 1. List of Baseline Parameter Values Used in Simulations and Their
Sources.
Parameter Value Reference
a1 0.4621 d
1 [7]*
a2 0.4621 d
1 [7]y
d1 0.3812 d
1 Best fit to data of Ellis et al. [14]
d2 0.4765 d
1 [7]z
h1 0.8
x1 1.18–1.35 Best fit
x2 0.25–1.0 Best fit
P0 0.995 [8]
§
Dp 10
10 cm2 s1 [24]
Dq 10
10 cm2 s1 [24]
*Berges et al. [7] report that malignant prostatic cells from five different
patients had an average cell cycle time of 48 ± 5 hours. Proliferation rate
varies with cell line; we therefore base this parameter on cells dividing once
every 36 hours.
yBerges et al. [7] noted no significant change in the proliferation rate of AI
cells when compared with metastatic cancer cells in untreated hosts.
zBerges et al. [7] noted a two-fold increase in the percentage of AI cells dying
per day when compared to metastatic cancer cells in untreated hosts. We
modified this to a 25% increase in the apoptotic rate, which is sufficient result
in the exponential decline of any initial population of AI cells.
§Based on the observation that AI cells were not detectable before ADT [14].
Figure 2. Best fit of mathematical model of tumor volume versus time to the
experimental data of [14]. Given the proliferation rate listed in Table 1, this
simulation was used to estimate the apoptotic rate of the AD cells, dp.
(4)
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days 28 to 112, there was a progressive decrease in the
apoptotic index [16].
Comparison with Experimental Data
LuCaP Xenografts Figure 5 compares the mathematical
model to experimental data [10] that exhibits three types
of responses to therapy. For the minimal and intermediate
responses, the best fit parameters are associated with a
15% decrease net proliferation of AD cells (or equivalently,
an 18% increase in the apoptotic rate) and a 40% and 60%
decrease in the apoptotic rate of the AI cells (x2 = 0.6, 0.4,
respectively). The best fit for the prolonged response corre-
sponds to a 20% increase apoptotic rate of the AD cells with
no decrease in the apoptotic rate of the AI cells.
There is an interesting conclusion that can be drawn
based on the parameters used in Figure 5 to fit the experi-
mental data. First, note that in all cases the net growth rate of
the AD cells is substantially lower than the precastration
value; however, it is still positive. In fact, it is impossible to fit
the data when ADT results in complete clearance of the AD
cells. The implication of this result is that some amount of
continual proliferation of the AD cells, even in the absence
androgen, occurs. This is consistent with some mechanism
of continual AR activation (whether by AR amplification or by
other pathways), and is required to match the experimental
data of Ellis et al. [14].
A comparison of the mathematical model and the exper-
imental data of Bladou et al. [16] is given in Figure 6. These
data show that ADT induced a significant decrease in the
Figure 3. Plot of tumor volume versus time before and after ADT as predicted by the mathematical model. In (A), the relative death rate of AI cells in the absence of
androgen (x2) is varied from 0.25 to 1.0. Tumor growth dynamics range from rapid relapse to prolonged remission or complete regression. (B) Highlights the case
when x2 = 0.5 and illustrates the exponential tumor growth before treatment, the transient androgen-sensitive period immediately after ADT, and the eventual AI
relapse.
Figure 4. Plot of the tumor’s proliferative and apoptotic activity versus time.
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tumor growth rate for the first 7 days postcastration and a
progressive increase thereafter. In Figure 5, x2 = 1.19 and
x2 = 0.6, which again suggests the continual proliferation of
AD cells even when androgen levels are low.
LNCaP Xenografts Figure 6 compares the mathematical
model to experimental data of Chen et al. [12] for the growth
of LNCaP cells in castrated mice. For these simulations,
we have removed the assumption that the tumor is com-
prised of cells that are BCL2-positive. Therefore, the only
mechanism for hormone-refractory tumor growth is up-
regulation and increased activation of the androgen receptor.
The mathematical model predictions are very close to
the experimental data and highlight the fact that upregulation
Figure 5. Best fit of the mathematical model to the experimental data of Ellis et al. [14] for normalized tumor volume versus time post-ADT.
Figure 6. Best fit of the mathematical model to the experimental data of Bladou et al. [16] for normalized tumor volume versus time post-ADT.
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of the androgen receptor is sufficient to cause AI tumor
growth.
Discussion
The question of whether AI growth of prostate cancer is due
to adaptation of AD cells (by amplification of the androgen
receptor or some other mechanism) or to clonal selection of
AI cells is yet unanswered. In an effort to assist in the
understanding of hormone-refractory prostate cancer and
mechanisms that possibly mediate this disease, we propose
a mathematical model that describes both the pretreatment
growth and the eventual post-ADT relapse of human pros-
tate cancer xenografts (LuCaP 23 and LNCaP). Simulations
of the model with polyclonality and decreased apoptosis of
the AI cells predict that for certain parameter values, ADT
can result in prolonged remission of the tumor or in AI
relapse. In agreement with experimental observations, the
relapse is associated with decrease in apoptotic activity
without an increase in proliferation. The mathematical model
predicts that this mechanism alone overestimates the tumor
reduction during the androgen-sensitive period and is inca-
pable of matching the experimental data for tumor volume as
a function of time post-ADT. This overestimation suggests
that factors that allow for the survival of some fraction of
AD cells may also be operative and highlights the impor-
tance of eliminating the continual proliferation of AD cells
after therapy.
Another potentially crucial factor associated with hor-
mone-refractory cancer is increased androgen-receptor ac-
tivation [4,9,12–15,23], which could allow for the reduced
but continual proliferation of AD cells even when androgen
levels are suboptimal. In fact, Chen et al. [12] recently found
that an increase in androgen receptor mRNA was the only
change that could be consistently associated with the devel-
opment of hormone resistance across seven human prostate
cancer xenografts (LuCaP and LNCap included). When
parameters of the model are changed to allow for effects of
upregulation and increased receptor activation in combina-
tion with decreased apoptosis, simulations show that the two
mechanisms together agree with the LuCaP experimental
data. These results imply that both increased BCL2 expres-
sion in AI cells and increased androgen receptor activation in
AD cells may contribute to the recurrent growth of LuCaP 23
xenografts.
When the mathematical model is compared with the
experimental data for hormone-insensitive LuCaP xeno-
grafts, there is no need to include mechanisms that bypass
the functional importance of the androgen receptor. The
model prediction agrees with experimental observations that
upregulation and increased receptor activation is sufficient to
result in AI tumor growth.
The model presented here is a preliminary study of
possible causes of the continued growth of prostate cancer
after ADT. The possibility of adaptation of AD cells is consid-
ered by changing the parameters of thismodel to describe the
continual proliferation of AD cells in the androgen-depleted
conditions occur posttherapy. A future investigation will mod-
ify and extend this model to describe the specific adaptation
of AD cells by particular pathways, including gain of function
of the androgen receptor [10], which result in increased
receptor activation in response to low androgen levels. Such
an investigation will assist in determining which mechanisms
of receptor activation, alone and in combination, lead to
relapse that is consistent with experimental data. The math-
ematical model described in this paper and the extensions
alluded to above provide a quantitative method for studying
the possible causes of AI prostate cancer growth and can be
used to test novel therapeutic strategies targeted at hor-
mone-refractory prostate cancer.
Figure 7. Comparison of the mathematical model to the experimental data of Chen et al. [12] for tumor volume versus time in castrasted mice implanted with
LNCaP tumor xenogarfts. In thse experiments tumor size was measured weakly and scored positive when size reached 40mm3.
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